Gamitrinib TPP is primarily utilized in the field of cancer research and therapy due to its targeted action on heat shock proteins (HSPs) within mitochondria. It is designed to inhibit the function of HSP90, a chaperone protein that plays a critical role in the stability and function of various oncogenic proteins. By disrupting HSP90 activity in mitochondria, Gamitrinib TPP induces mitochondrial dysfunction and triggers apoptosis specifically in cancer cells, sparing normal cells. This selective mechanism makes it a promising candidate for treating tumors that are resistant to conventional therapies. Its application is particularly significant in preclinical studies aimed at understanding and combating drug-resistant cancers, such as those in breast, prostate, and pancreatic malignancies.